Greater improvement in quality of life outcomes in patients using fixed-combination calcipotriol plus betamethasone dipropionate aerosol foam versus gel: results from the PSO-ABLE study
- 14 Downloads
Health-related quality of life (HRQoL) measures provide patient-centred evaluations of response to treatment. In the 12-week, Phase III PSO-ABLE study, fixed-combination calcipotriol 50 μg/g as hydrate (Cal) plus betamethasone 0.5 mg/g as dipropionate (BD) aerosol foam was significantly more effective for the treatment of psoriasis than Cal/BD gel.
To compare HRQoL in mild-severe psoriasis vulgaris patients (involving 2-30% body surface area) over 12 weeks of treatment with Cal/BD foam or gel.
HRQoL was assessed using: Dermatology Life Quality Index (DLQI), EuroQoL-5D-5L-PSO (EQ-5D), and Psoriasis QoL (PQoL-12) questionnaires (baseline, Weeks 4, 8 and 12); DLQI score of 0/1 (range: 0-30) and weighted EQ-5D utility index score of 1 (range: 0-1) indicates there is no impact on a patient’s QoL and perfect health, respectively. Itch, itch-related sleep loss, and work impairment were also assessed.
In total, 463 patients were randomized to the study (Cal/BD foam, n = 185; Cal/BD gel, n = 188; foam vehicle, n = 47; gel vehicle, n = 43). Significantly more Cal/BD foam patients achieved DLQI scores of 0/1 at Weeks 4 (45.7% vs 32.4%; p = 0.013) and 12 (60.5% vs 44.1%; p = 0.003) than Cal/BD gel patients. Cal/BD foam significantly improved EQ-5D utility index (0.09 vs 0.03; p<0.001) and PQoL-12 scores (-2.23 vs -2.07; p = 0.029) from baseline to Week 4 versus Cal/BD gel. Itch, itch-related sleep loss, and work impairment improved more with Cal/BD foam than gel.
Cal/BD foam demonstrated greater HRQoL improvement in patients with psoriasis than Cal/BD gel over 12 weeks of treatment.
Key wordsaerosol foam calcipotriol betamethasone dipropionate psoriasis vulgaris quality of life
Unable to display preview. Download preview PDF.
- 2.Langley RG, Krueger GG, Griffiths CE. Psoriasis:epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005;64(Suppl 2):ii18–23.Google Scholar
- 7.Bewley A, Page B. Maximizing patient adherence for optimal outcomes in psoriasis. J Eur Acad Dermatol Venereol 2011;25(Suppl 4):9–14.Google Scholar
- 8.Hollesen Basse L, Olesen M, Lacour JP, Queille–Roussel C. Enhanced in vitro skin penetration and antipsoriatic effect of fixed combination calcipotriol plus betamethasone dipropionate in an innovative foam vehicle. J Invest Dermatol 2014;134:S33, abst 192.Google Scholar
- 10.Lebwohl M, Tyring S, Bukhalo M, et al. Fixed combination aerosol foam calcipotriene 0.005% (Cal) plus betamethasone dipropionate 0.064% (BD) is more efficacious than Cal or BD aerosol foam alone for psoriasis vulgaris:a randomized, double–blind, multicenter, three–arm, Phase II study. J Clin Aesthet Dermatol 2016; 9: 34–41.PubMedPubMedCentralGoogle Scholar
- 14.Paul C, Stein Gold L, Cambazard F, et al. More rapid improvement in quality of life with fixed combination calcipotriene plus betamethasone dipropionate aerosol foam versus topical suspension (PSO–ABLE study in patients with psoriasis vulgaris). J Am Acad Dermatol 2016:P3712.Google Scholar
- 18.Leonardi C, Bagel J, Yamauchi P, et al. The aerosol foam formulation of the fixed combination calcipotriene plus betamethasone dipropionate improves the health–related quality of life in patients with psoriasis vulgaris:results from the randomized PSO–FAST study. J Drugs Dermatol 2016; 15: 981–7.PubMedGoogle Scholar